Treatment of atopic dermatitis with dupilumab in Taiwan: dynamic changes of IgE levels as a potential response biomarker

Eur J Dermatol. 2019 Dec 1;29(6):658-659. doi: 10.1684/ejd.2019.3661.

Authors

Tzu Hung Huang¹, Yin-Chun Chen¹, Sheng-Yiao Lin¹, Szu-Hao Chiu¹, Ting-Ting Yang¹, Li-Wen Chiu¹, Yang-Yi Chen², Cheng-Che E Lan³

Affiliations

¹ Department of Dermatology, Kaohsiung Medical University Hospital.
² Department of Dermatology, Kaohsiung Medical University Hospital,, Graduate Institute of Clinical Medicine, College of Medicine.
³ Department of Dermatology, Kaohsiung Medical University Hospital,, Graduate Institute of Clinical Medicine, College of Medicine,, Department of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

PMID: 31903962
DOI: 10.1684/ejd.2019.3661

No abstract available

Publication types

Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Biomarkers / blood
Dermatitis, Atopic / blood*
Dermatitis, Atopic / drug therapy*
Female
Humans
Immunoglobulin E / blood*
Male
Taiwan
Young Adult

Substances

Antibodies, Monoclonal, Humanized
Biomarkers
Immunoglobulin E
dupilumab